34 results about "Glyceryl behenate" patented technology

The application relates to the technical field of pharmaceutical preparations, and particularly discloses a propranolol hydrochloride tablet with low N-nitrosopropylol impurity content and a preparation method thereof. The propranolol hydrochloride tablet with low N-nitrosopropylol impurity content comprises the following components in parts by weight: 0.2-0.3 parts of propranolol hydrochloride, 2.0-2.3 parts of mannitol, 0.2-0.3 parts of glycerin behenate and 0.05-0.1 parts of magnesium stearate. In the application, mannitol, glycerin behenate and magnesium stearate are used as excipients, the mannitol, the glycerin behenate and the magnesium stearate all have high fluidity, and the glycerin behenate has lubricating and excipient effects, so that the compression of the tablets is facilitated.

The present invention discloses an atovaquone enteric-coated tablet, which preparation comprises atovaquone, glyceryl behenate, tyloxapol, a filler, a binder, a disintegrant and an enteric coating, and the particle size D90 of atovaquone is 30-50 μm. The atovaquone enteric-coated tablet of the present invention has a stable and continuous release, high bioavailability, can be released at a specific position in the intestine, reduce the hepatic circulation, thereby reducing the occurrence of phenomena such as liver injury, and has no phenomena such as sticking to the punch and capping during the tabletting process, with qualified and stable quality, and ensures its dissolution performance and stability.

The invention discloses a melogabalin besylate solid pharmaceutical composition, a preparation and a preparation method of the melogabalin besylate solid pharmaceutical composition. The solid pharmaceutical composition comprises melogabalin besylate, and further comprises L-tartaric acid, ascorbyl palmitate and a nonionic ester compound selected from at least one of hydrogenated castor oil and glyceryl behenate. According to the melogabalin besylate solid pharmaceutical composition, due to the adoption of the combination of the L-tartaric acid, the ascorbyl palmitate and at least one nonionic ester compound selected from the hydrogenated castor oil and the glyceryl behenate, through the synergistic effect of the L-tartaric acid, the ascorbyl palmitate and the nonionic ester compound, the stability obviously superior to that in the prior art can be achieved; and the solid preparation has excellent dissolution performance.

The invention discloses a doxorubicin hydrochloride liposome, a preparation and application thereof, and belongs to the technical field of antitumor drug preparations. The doxorubicin hydrochloride liposome disclosed by the invention is prepared from doxorubicin hydrochloride, phospholipid, cholesterol, beta-sitosterol, cucumber alcohol, glyceryl behenate and a pH buffer agent as raw materials through a specific preparation method. The components in the formula have a synergistic effect to stabilize the lipid membrane, the preparation process is simple, and industrialization is easy to realize. Experiments show that the liposome is high in encapsulation efficiency, and the injection prepared from the liposome is better than commercially available products in stability and has good application prospects.

The present invention relates to the technical field of pharmaceutical preparations, and specifically discloses a piribedil sustained-release tablet and a preparation method thereof. The piribedil sustained-release tablet comprises a tablet core and a coating layer, wherein the tablet core comprises piribedil, a sustained-release material, an adhesive, and a lubricant; the sustained-release material is selected from at least one of glyceryl behenate, hydrogenated oil, or talc; and the coating layer comprises a water-soluble coating material and a water-insoluble coating material. The sustained-release material is prepared into uniform hydrophobic dry granules by granulation, and then the piribedil raw material is mixed with sustained-release granules of a specific particle size so that the main drug is embedded in the gaps between the sustained-release granules, and then tableting is performed to prepare the tablet core. During the preparation process, the influence of temperature and humidity on the piribedil raw material is avoided, and the impurity stability during the preparation process is significantly improved. The dissolution curve of the prepared piribedil sustained-release tablet is similar to that of the original preparation, and the original product can be replaced.

The invention discloses an encapsulated oil-in-water type composition and a preparation method thereof. The encapsulated oil-in-water type composition comprises the following components in percentage by weight: 0.1-1% of retinol; the oil-phase thickening agent is selected from one or more of dextrin palmitate, a castor oil / IPDI (isophorone diisocyanate) copolymer, an HDI (hexamethylene diisocyanate) / trihydroxymethyl hexyl lactone cross-linked polymer, glyceryl behenate, a hydrogenated (styrene / butadiene) copolymer and dibutyl lauroyl glutamine; the oil-phase thickening agent is selected from one or more of dextrin palmitate, a castor oil / IPDI (isophorone diisocyanate) copolymer, an HDI (hexamethylene diisocyanate) / trihydroxymethyl hexyl lactone cross-linked polymer, glyceryl behenate, a hydrogenated (styrene / butadiene) copolymer and dibutyl lauroyl glutamine; 10%-20% of an oil component, wherein the oil component comprises caprylic acid / capric triglyceride; 0.1%-5% of a rheology modifier; 5-20% of a humectant; and the balance of water. The capsule product has good slow release property. According to the composition disclosed by the invention, high-content addition and high-efficacy performance of the retinol are realized, meanwhile, good formula stability can also be realized, and the problem of skin irritation caused by the retinol is improved.

The present application relates to the technical field of pharmaceutical preparation, in particular to a tranexamic acid composition and a preparation method thereof, according to weight parts, the tranexamic acid composition comprises: tranexamic acid 100 parts, polyvinyl alcohol 5-9 parts, corn starch 1-3 parts, low-substituted hydroxypropyl cellulose 4-8 parts and lubricant 1-4 parts; the lubricant comprises glyceryl behenate. The tranexamic acid composition has less impurities than a reference preparation, and there is no obvious change in dissolution under high-temperature conditions; through accelerated and long-term test research, evaluation indexes such as dissolution curve, content, dissolution rate and related substances all meet the requirements, and there is no significant change compared with 0 days, the quality is stable, the quality is consistent with that of the reference preparation, and the bioequivalence in vivo is achieved, the clinical substitution with the reference preparation is realized, the price is lower, the accessibility is high, and the medication burden of the public is reduced.

The invention discloses a brovudine cream for treating herpes zoster and a preparation method of the brovudine cream. Specifically, the invention provides a cream which comprises the following components in percentage by mass: 0.1-5% of bromovudine, 5-45% of an organic solvent, 0.3-10% of an emulsifier, 15-55% of an oil phase matrix and water, the cream is an oil-in-water type cream; and any one of the following conditions is met: (C1) the emulsifier comprises 15-hydroxystearic acid polyethylene glycol ester; (C2) the oil phase matrix comprises glyceryl behenate. The brovudine cream provided by the invention has one or more positive progressive effects of good safety, small side reaction, good stability and good treatment effect.

A solidification and solubilization method for a progesterone self-emulsifying liquid formulation and a progesterone self-emulsifying solid formulation. A curing agent is mixed with a progesterone self-emulsifying liquid formulation, wherein the curing agent comprises one or more of lauroyl polyoxyethylene-32 glyceride, polyoxyethylene-8 glyceryl behenate, polyethylene glycol-32 stearate and stearoyl polyoxyethylene glyceride. The melting point of the progesterone self-emulsifying liquid formulation is increased to above room temperature by means of a specific curing agent, such that the progesterone self-emulsifying liquid formulation is in a solid state at room temperature, thereby obtaining a progesterone self-emulsifying solid formulation; moreover, the drug loading capacity of progesterone is enhanced. The solidification and solubilization method can not only improve the solubility of the progesterone to avoid crystallization and precipitation, and improve the uniformity of the formulation, but also improve the self-emulsifying ability of the progesterone self-emulsifying formulation without affecting the release rate of progesterone in the self-emulsifying formulation.

This invention discloses a guanifacine hydrochloride sustained-release tablet and its preparation method. The method includes placing a granulated / mixed, tableted guanifacine hydrochloride pharmaceutical composition into a hot air device for drying. The hot air device is selected from a coating machine or an oven, and the hot air temperature ranges from 30 to 70°C. After drying, the resulting guanifacine hydrochloride sustained-release tablet has a moisture content ≤4.0% by weight, preferably ≤3.5% by weight. The guanifacine hydrochloride pharmaceutical composition contains guanifacine hydrochloride, lactose, microcrystalline cellulose, hydroxypropyl methylcellulose, methacrylate copolymer, fumaric acid, glyceryl behenate, sodium stearate fumarate, and micronized silica gel. This hot air drying process effectively controls the total impurities of the guanifacine hydrochloride sustained-release tablets to ≤1.0% and the single impurities to ≤0.1%. This process improves the safety and stability of the drug, is easy to operate, and is suitable for commercial production.

The invention relates to gummy candy or soft sweets containing an improved functional component which consists of encapsulated and / or granular functional components and is released in a controlled manner over time. The present invention relates to soft sweets, in particular soft sweets, in which encapsulated and / or granular functional ingredients have been suitably adjusted to avoid significant changes in solubility and pH of the soft sweets and without any impediment on the gelling process in the manufacture of the soft sweets, in which the improved functional ingredients comprise active substances or functional ingredients (3) contained in capsules or particles (4), which are excipients of microcapsules, and in which the active substances or functional ingredients (3) are contained in the capsules or particles (4). Wherein the excipient is any one or more of the following excipients: glyceryl behenate (E471), hydroxy propyl cellulose (HPMC) and / or ethyl cellulose. In addition, the excipient proportion of the functional component must be between 20% and 80%.

The invention discloses indole coated particles for livestock and poultry and a preparation method and application thereof, the indole coated particles are prepared from indole and a dual-lipid carrier system, the dual-lipid carrier system comprises hydrogenated vegetable oil and glyceryl behenate in a weight ratio of 1: (2-3), and the mixing weight ratio of the indole to the dual-lipid carrier system is 1: (3-4). In the formula, the hydrogenated vegetable oil and the glyceryl behenate are mixed and embedded according to a reasonable proportion, so that indole can be released by a diffusion-dominated mechanism, and relative balance of taste masking and controlled release is realized. Meanwhile, the indole coated particles can reduce the stress reaction and feed intake reduction of livestock and poultry caused by the peculiar smell of the indole, and the growth limitation of the livestock and poultry is avoided. The preparation method of the product is simple, and the production cost can be effectively reduced.

The invention relates to the field of pharmaceutical preparations, in particular to butanedisulfonic acid ademetionine enteric-coated tablets and a preparation method thereof. The invention provides a butanedisulfonic acid ademetionine enteric-coated tablet. The butanedisulfonic acid ademetionine enteric-coated tablet comprises a tablet core and an enteric coating layer, wherein the tablet core comprises butanedisulfonic acid adenosyl methionine, glyceryl behenate, a filling agent, a disintegrating agent and a lubricating agent; the enteric coating layer comprises a coating premix; the coating premix comprises hydroxypropyl methylcellulose acetate succinate and an anhydrous solvent. The ademetionine butanedisulfonate enteric-coated tablet obtained by matching the glyceryl behenate and the hydroxypropyl methylcellulose acetate succinate is lower in water content, degradation of S-S ademetionine and increase of related substances are not obvious under an accelerated test condition, the product stability is better, and the medication safety of a patient can be better ensured.

To provide an oily solid cosmetic comprising, as a main component of a solid oil, a natural-derived substance, exhibiting excellent pick-up by fingers, smooth spreadability, and high stability.SOLUTION: An oily solid cosmetic comprising: (a) 3-15 mass% of a solid oil; (b) 0.1-2.5 mass% of glyceryl behenate; (c) 0.1-2.5 mass% of polyglyceryl-6 octastearate; and (d) a liquid oil, the solid oil (a) comprising 70 mass% or more of sunflower seed wax and / or carnauba wax based on the total mass of the solid oil, and the liquid oil (d) comprising 50 mass% or less of hydrocarbon oil based on the total mass of the liquid oil.SELECTED DRAWING: None

The application discloses a composition with the effect of auxiliary treatment of arthritis and a preparation method and application thereof, and the composition comprises the following preparation raw materials in parts by weight: non-denatured type II collagen 5-15 parts, curcuma longa extract 56.8-100 parts, frankincense extract 18.7-39.8 parts, sophora flower bud extract 15-28.5 parts, chondroitin sulfate 20-30 parts, glyceryl behenate 15-25 parts, chitosan 3-7.5 parts, sodium deoxycholate 3-8 parts, polyethylene glycol-15 hydroxystearate 5-15 parts, anti-knotting agent 1-3 parts, curing agent 5-15 parts and filling agent 15-25 parts. The application can treat arthritis through the trinity of immune-mechanical-metabolic pathways, and the effect is remarkable and fast, and has a certain residual effect.

The present invention provides a camellia oil anti-wrinkle, anti-aging, antioxidant cream and a preparation method thereof, belonging to the technical field of cosmetics. The preparation method comprises the following steps: adding glycerol, 1,3-butanediol, sorbitol, sodium hyaluronate, ethylhexylglycerin, methylparaben into water according to the formula, heating and stirring for 10-20 min, then successively adding camellia oil, plant fermentation active substances, squalane, L-arginine, tocopherol, PEG-7 glyceryl cocoate, cetearyl alcohol, glyceryl behenate and continuing to stir for 20-40 min, then homogenizing for 4-6 min, sterilizing, and discharging to obtain the product; wherein, the plant fermentation active substances are obtained by crushing, air explosion and fermentation treatment of Erigeron breviscapus and Plantago asiatica, and then through heating extraction and supercritical extraction; the fermentation bacteria are Bacillus subtilis and / or Lactiplantibacillus plantarum. The cream of the present invention has stable storage performance, is mild and moisturizing, can timely supplement moisture and nutrition to the skin, and has excellent antioxidant, anti-aging and anti-wrinkle effects.

[Problem] The purpose of the present invention is to provide a water-in-oil type emulsion cosmetic which can be efficiently produced and has improved stability in high-temperature and low-temperature regions. [Solution] A water-in-oil emulsion cosmetic according to the present invention is characterized by comprising: (A) an ester of a C10-22 fatty acid and a polyol having at least three hydroxyl groups in the molecule; (B) one or more substances selected from the group consisting of (B-1) amino acids or salts thereof and (B-2) bivalent or higher inorganic salts; (C) glyceryl behenate / eicosane diacid ester; and (D) water.

The invention provides an agomelatine tablet composition as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The preparation method of the agomelatine tablet composition comprises the following steps: pre-mixing agomelatine with the filler, the adhesive and the disintegrating agent according to the weight percentage by using a high-shear wet type granulator; adding purified water into the high-shear wet type granulator for granulating, and stirring and shearing at the same time; the wet particles are transferred into a fluidized bed to be dried after being finished, and dry particles are obtained; finishing the dry particles, adding a lubricant, and blending to obtain total mixed particles; and adding the total mixed particles into a high-speed tablet press for tabletting. According to the invention, glyceryl behenate is adopted to replace stearic acid, so that the sticking problem caused by lower melting point of stearic acid in the tabletting process is avoided, the tablet pushing force can be reduced, and the compressibility in tablet and capsule production is improved; and the temperature control range of the sheet bed can be expanded to 35-50 DEG C.

The invention discloses a 1-(5-oxohexyl) theobromine sustained-release tablet, the 1-(5-oxohexyl) theobromine sustained-release tablet is composed of a tablet core and a sustained-release coating layer, the tablet core (based on the total weight of the tablet core) is prepared from the following components in parts by weight: 360-450 parts of 1-(5-oxohexyl) theobromine, 50-200 parts of a skeleton sustained-release material, 5-15 parts of an adhesive and 5-10 parts of a lubricant, the matrix sustained-release material is selected from glyceryl behenate and / or polyoxyethylene, preferably, the matrix sustained-release material is selected from glyceryl behenate and polyoxyethylene, the weight ratio of glyceryl behenate to polyoxyethylene is (0.5-2): 1, and the adhesive is prepared into a 95% ethanol solution of 5% povidone K30.

The invention relates to the technical field of high polymer materials, and particularly discloses a hydrophobic controlled-release coating material and a preparation method thereof.The hydrophobic controlled-release coating material comprises a material P and a material I according to the mass ratio of 100: 70-110; the material P is prepared from the following components in parts by mass: 15 to 55 parts of modified recycled regenerated oil, 10 to 30 parts of dicarboxylic acid, 5 to 20 parts of propylene glycol, 10 to 50 parts of polyhydric alcohols, 1 to 3 parts of amine catalysts, 2 to 4 parts of amino acid derivatives and 1 to 3 parts of modified starch; the material I is prepared from the following components in parts by mass: 1 to 3 parts of glyceryl behenate and 10 to 14 parts of vegetable oil-based isocyanate; hydrogenated modified recycled regenerated oil is used as a base material to provide a long-chain hydrophobic skeleton and active carboxyl, glyceryl behenate provides a crystallization hydrophobic micro-area, and an amine catalyst and an amino acid derivative cooperate to reduce reaction activation energy; through hydrophobic network construction, cross-linking enhancement and degradation regulation, a coating structure with high hydrophobicity and precise controlled release is formed; the material is degradable, does not pollute soil, has good hydrophobicity, and can effectively control the dissolution rate of the chemical fertilizer.

The application discloses a solid pharmaceutical composition of meloxicam benzene sulfonic acid, a preparation and a preparation method thereof. The solid pharmaceutical composition comprises meloxicam benzene sulfonic acid, and further comprises L-tartaric acid, ascorbic acid palmitate and a non-ionic ester compound selected from at least one of hydrogenated castor oil and glycerol behenate. The solid pharmaceutical composition of meloxicam benzene sulfonic acid has the stability obviously superior to that of the prior art, and the dissolution performance of the solid preparation is excellent, due to the combination of L-tartaric acid, ascorbic acid palmitate and the non-ionic ester compound selected from at least one of hydrogenated castor oil and glycerol behenate, and the synergistic effect of the three.

The application discloses a reba piate tablet and a preparation method thereof. The tablet comprises reba piate, a carrier material, a filler, a binder, a disintegrant, a lubricant and pharmaceutically acceptable excipients. The carrier material is glyceryl behenate and poloxamer copolymer. The reba piate tablet of the application avoids the increase of impurities in a high-temperature and high-humidity environment, reduces the agglomeration of the raw drug caused by static electricity, adjusts the release rate of the reba piate tablet, and has a simple preparation process and is suitable for industrial mass production.

The invention relates to the technical field of cosmetics, and particularly discloses a lip skin protective agent and a preparation method thereof. The invention relates to a lip skin protective agent, which is prepared from the following raw materials in percentage by mass: 36 to 75 percent of squalane, 10 to 30 percent of natural vegetable fat, 7.3 to 21 percent of active substances, 2 to 7 percent of glyceryl behenate, 1 to 6 percent of lecithin, 1 to 6 percent of polyglycerol-4 isostearate and 0.1 to 2 percent of antioxidants. The active substances comprise 7 to 15 percent of phytosterol, 0.1 to 4 percent of ceramide and 0.2 to 2 percent of palmitoyl active peptide. The lip skin protective agent is in an ointment dosage form, can be used for lip care, and has the advantages of effectively improving ecdysis and chapping of lips, fading cheilogramma and improving the barrier and anti-irritation ability of the lip skin.

The invention belongs to the field of biological medicine, and particularly relates to an oral dye solid composition and application thereof. The invention provides an oral dye solid composition. The composition comprises a lipophilic matrix, a sustained-release material and other pharmaceutically acceptable auxiliary materials, the lipophilic matrix is glyceryl behenate or carnauba wax. The solid composition provided by the invention has good stability, especially good stability at high temperature. And after long-time storage under a high-temperature condition, the content of the specific impurity azurol B is slowly increased, and the dissolution speed is slightly influenced.

The present invention is in the field of pharmacy. More specifically, the present invention discloses an extended-release pharmaceutical composition comprising trazodone and / or its salts as a water-soluble active compound, a lipophilic matrix-forming agent selected from the group consisting of glyceryl behenate and hydrogenated castor oil, and povidone in an amount of less than 10% by weight. Additionally, a process for producing said composition is disclosed.

The invention discloses an oral solid preparation of melogabalin benzene sulfonate, which comprises melogabalin benzene sulfonate, a sugar alcohol filler, a lubricant and a disintegrating agent, and the lubricant is a combination of glyceryl behenate and other lubricants. The other lubricant is selected from one or more of stearic acid, sodium lauryl sulfate, magnesium lauryl sulfate, magnesium aluminum metasilicate, magnesium stearate and sodium stearyl fumarate. According to the present invention, the growth change of the related substances in the melogabalin besylate preparation is researched, the prescription of the oral solid preparation is optimized, and the fact that the glyceryl behenate can significantly improve the stability of the melogabalin besylate preparation is accidentally found, and the preparation method is suitable for various preparation processes, and is more suitable for industrial production.

Mascara compositions with improved aesthetics are provided. Such compositions generally include a plurality of waxes including sunflower seed wax and a plurality of behenates including tribehenin and behenyl behenate. The plurality of waxes may include the sunflower seed wax, the tribehenin, the behenyl behenate, and at least one additional wax. The plurality of waxes may be present in a total amount of about 5% to about 35% by weight of the mascara composition. The combined total amount of sunflower seed wax, tribehenin, and behenyl behenate may be about 5% to about 20% by weight of the composition. The mascara composition may optionally include no more than about 10% water, such as about 2% to about 7%, by weight of the mascara composition.

The present invention relates to the field of pharmaceutical technology, and particularly relates to an agomelatine pharmaceutical composition, a preparation method thereof and an application thereof. The agomelatine pharmaceutical composition comprises inner layer microparticles, a coating layer and outer layer excipients; the inner layer microparticles comprise the following raw materials: agomelatine, hypromellose, mannitol and colloidal silicon dioxide; the coating layer is obtained by coating a chitosan-sodium carboxymethyl starch suspension on the surface of the inner layer microparticles; the outer layer excipients comprise the following raw materials: glyceryl behenate, sucrose, polyvinylpyrrolidone, sodium carboxymethyl starch and magnesium stearate. The agomelatine pharmaceutical composition provided by the present invention has stable dissolution, extremely low impurities, controllable quality and excellent stability, and can be used for treating depression and related diseases.

This invention discloses a method for synergistic moisture-proof and flavor-masking coating of traditional Chinese medicine granules, belonging to the field of pharmaceutical formulation technology. The method includes: S1, obtaining porous starch by enzymatic hydrolysis, ferric chloride complexation, and integrated twin-screw extrusion-enzymatic hydrolysis of corn starch, followed by surface ammoniation modification with 3-aminopropyltriethoxysilane and then mixing and adsorbing with traditional Chinese medicine granules to obtain granules covered with a sacrificial inner layer; S2, alternately coating the granule surface with sodium carboxymethyl cellulose and poly-L-arginine through layer-by-layer self-assembly to form a composite intermediate layer; S3, in-situ coordination polymerization of tannic acid and ferric chloride on the granule surface to form a polymer coating layer; S4, freezing the granules and then using a mixture of behenicol glyceryl ester and cocoa butter as the hot-melt coating material, followed by fluidized bed hot-melt coating. This invention solves the problems of the prior art, such as the separation of moisture-proof and flavor-masking functions, easy escape of volatile oils, and insufficient coating density. The resulting granules have low moisture absorption, high volatile oil retention, long-lasting flavor masking, and precise pH-responsive drug release.

This invention discloses a squalane lip essence oil and its preparation process, comprising the following raw material components: Phase A: tridecyl trimellitate; diisostearyl malate; ethylhexyl palmitate; 972 hydrogen powder; Phase B: glyceryl behenate / eicosadecanate; polyisobutylene; Phase C: hydrogenated (styrene / isoprene) copolymer / pentaerythritol tetra(bis-tert-butylhydroxyhydrogenated cinnamic acid) ester; plant squalane; camellia seed oil; shea butter; avocado oil; baobab oil; comfrey oil; vitamin E acetate; Phase D: pigment; The lip essence oil of this invention can significantly moisturize and nourish, and has repairing, anti-inflammatory and soothing effects on the lip skin.